Literature DB >> 16987546

Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.

Natasja de Bruin1, Bruno Pouzet.   

Abstract

Episodic memory has been found to be impaired in several neuropsychiatric disorders. The object recognition task (ORT), introduced by Ennaceur and Delacour [Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats: 1. Behavioral data. Behav Brain Res 1988; 31: 47-59.], is a method to measure a specific form of episodic memory in rats and mice. It is based on the spontaneous behavior of rodents and can be considered as a retention test completely free of reference memory components. Therefore, the ORT has been increasingly used as an experimental tool in assessing drug effects on memory and investigating the neural mechanisms underlying learning and memory. In the present study, the main goal was to evaluate the effects of galantamine in Swiss mice in the ORT on scopolamine-induced deficits and with different retention intervals. Mice had a good object recognition memory at the 15 min retention intertrial interval (ITI). Object discrimination was absent at the longer intervals (1 h, 4 h and 24 h). Galantamine (10 mg/kg, administered s.c., 30 min prior to acquisition) partially reversed effects of scopolamine (0.63 mg/kg, administered s.c., 30 min prior to acquisition) and normalized performance to control levels. A lower dose of galantamine (0.63 mg/kg) was also investigated when two different retention intervals (15 min and 1 h) were used. Galantamine (0.63 mg/kg) had no adverse effects. Solvent-treated mice in the 1 h ITI condition did not discriminate between the novel and the familiar object (discrimination index was equal to zero), while galantamine (0.63 mg/kg)-treated mice attained a good object recognition memory performance. In conclusion, galantamine was shown to possess memory-enhancing effects in two conditions that reduced object discrimination: scopolamine-induced deficits and when a longer retention interval was used.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987546     DOI: 10.1016/j.pbb.2006.08.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  27 in total

1.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

Review 2.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

3.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

4.  Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.

Authors:  Latha Ramakrishnan; Christina Amatya; Cassie J DeSaer; Zachary Dalhoff; Michael R Eggerichs
Journal:  Invert Neurosci       Date:  2014-01-09

5.  The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.

Authors:  Scott J Webster; Christina A Wilson; Chih-Hung Lee; Eric G Mohler; Alvin V Terry; Jerry J Buccafusco
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice.

Authors:  Justin W Kenney; Michael D Adoff; Derek S Wilkinson; Thomas J Gould
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

Review 7.  Mouse pharmacological models of cognitive disruption relevant to schizophrenia.

Authors:  Jared W Young; Susan B Powell; Mark A Geyer
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

8.  Pharmacodynamic study of FS-0311: a novel highly potent, selective acetylcholinesterase inhibitor.

Authors:  Zhi Fei Wang; Jin Yan; Yan Fu; Xi Can Tang; Song Feng; Xu Chang He; Dong Lu Bai
Journal:  Cell Mol Neurobiol       Date:  2007-09-05       Impact factor: 5.046

9.  The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.

Authors:  Jerry J Buccafusco; Alvin V Terry; Scott J Webster; Daniel Martin; Elizabeth J Hohnadel; Kristy A Bouchard; Samantha E Warner
Journal:  Psychopharmacology (Berl)       Date:  2007-07-27       Impact factor: 4.530

10.  PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice.

Authors:  Silvia Lorrio; Alejandro Romero; Laura González-Lafuente; Rocío Lajarín-Cuesta; Francisco J Martínez-Sanz; Martín Estrada; Abdelouahid Samadi; Jose Marco-Contelles; María Isabel Rodríguez-Franco; Mercedes Villarroya; Manuela G López; Cristóbal de los Ríos
Journal:  ACS Chem Neurosci       Date:  2013-06-13       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.